Syntara Limited
Research Syntara Limited (UUDA) on Bullrun: market cap EUR 19.63M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerUUDA
- ExchangeF
- CountryAustralia
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 19.63M
- Financial periodFY2025
- Net income-AUD 7.92M
- Free cash flow-AUD 11.12M
Valuation Snapshot
latest market cap is EUR 19.63M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | -AUD 7.92M | -AUD 11.12M | n/a | -0.01 | AUD 15.08M | AUD 84.00K | AUD 16.02M |
| FY2024 | n/a | -AUD 15.14M | -AUD 14.49M | n/a | -0.02 | AUD 3.52M | AUD 233.00K | AUD 4.68M |
| FY2023 | AUD 5.77M | -AUD 11.36M | -AUD 7.42M | 53.1% | -0.02 | AUD 9.23M | AUD 2.04M | AUD 9.56M |
| FY2022 | AUD 7.43M | -AUD 1.94M | -AUD 16.41M | 100.0% | 0 | AUD 8.94M | AUD 4.29M | AUD 10.80M |
| FY2021 | AUD 6.68M | n/a | n/a | 100.0% | n/a | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-29 | EUR 19.63M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Syntara Limited
Syntara Limited, a clinical-stage drug development company, that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Syntara Limited's market cap?
Syntara Limited's market capitalization is EUR 19.63M.
What does Syntara Limited do?
Syntara Limited, a clinical-stage drug development company, that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate is amsulostat, which has completed Phase 2a clinical trial for the treatment of bone marrow cancer myelofibrosis, as well as in Phase 1c/2 clinical trial for patients with myelodysplastic syndrome and in Phase 1/2 clinical trial to treat pancreatic cancer.